Dr Lockman was a panelist for the Forum’s discussion on Treatment as Prevention.
Shahin Lockman is an Associate Professor in the Department of Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and an Assistant Professor at Harvard Medical School. Her research focuses on determining the best antiretroviral drug regimens to prevent mother-to-child transmission of HIV in Africa, and the treatment of mothers who have developed drug resistance as a result of the use of drugs to prevent mother-to-child transmission. She has conducted epidemiologic and clinical trials investigation related to HIV-1 (and tuberculosis) in southern Africa since 1996, focusing primarily on biomedical approaches to preventing mother to child transmission (MTCT) of HIV-1; treating women (and infants) with antiretroviral drugs following exposure to antiretrovirals for MTCT prevention; optimizing the health of HIV-infected mothers and HIV-exposed and -infected children; and studying the safest approaches to feeding HIV-exposed infants in resource limited settings. She is also investigating the effects of in utero exposure to HIV-1 and to antiretroviral drugs on long-term pediatric neurodevelopment and morbidity, mortality. Dr. Lockman also collaborates with other investigators on operational and epidemiologic research projects in Botswana related to infant male circumcision; programmatic improvement of MTCT prevention programs; HIV and malignancy; and community-based intensive combination prevention interventions (including antiretroviral “treatment for prevention”) to reduce HIV incidence. Finally, she is active in the Botswana Clinical Trials Unit, which participates in multicenter clinical trials among adults and children living with HIV.
